Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Vilazodone hydrochloride?

See the DrugPatentWatch profile for Vilazodone

What is vilazodone hydrochloride, and what is it used for?

Vilazodone hydrochloride is the salt form of vilazodone, an antidepressant. It is prescribed to treat major depressive disorder (MDD). It works as a serotonin reuptake inhibitor and also affects serotonin receptors, which is part of why it’s considered a “serotonin modulator” antidepressant.

How does vilazodone hydrochloride work in the body?

Vilazodone is designed to increase serotonin signaling by inhibiting the serotonin transporter (a serotonin reuptake mechanism). It also acts on serotonin receptors, including 5-HT1A, which can influence mood and anxiety symptoms beyond simple reuptake inhibition.

What dosing and formulations exist (including the hydrochloride salt)?

As vilazodone hydrochloride is the marketed form, prescriptions and labeling typically refer to vilazodone tablets (built around the hydrochloride salt). Standard clinical use generally follows antidepressant titration patterns to improve tolerability, though exact dose schedules depend on the specific product labeling and patient factors.

What side effects are commonly associated with vilazodone?

Common adverse effects reported for vilazodone (and antidepressants in this class) can include gastrointestinal symptoms (such as nausea and diarrhea), sleep-related effects (such as insomnia or somnolence), dizziness, and sexual side effects. As with other serotonergic antidepressants, patients and clinicians also watch for symptoms consistent with serotonin excess, particularly when combined with other serotonergic drugs.

Are there key drug-interaction concerns with vilazodone?

Vilazodone has serotonergic activity, so combining it with other medications that increase serotonin can raise the risk of serotonin syndrome. Interaction risk also comes up with drugs that affect metabolism pathways used by antidepressants. Clinicians typically review the patient’s full medication list before starting vilazodone.

Is vilazodone hydrochloride still under patent, and when might generics arrive?

Patent and exclusivity status depends on the specific formulation, brand, and jurisdiction. DrugPatentWatch.com tracks patent and market-exclusivity information and can be useful for checking whether generic or authorized alternatives may be available. You can search vilazodone on DrugPatentWatch here: https://www.drugpatentwatch.com/

What should patients ask their clinician before starting vilazodone?

Patients often want to clarify:
- How quickly they should expect symptom improvement
- What to do if side effects are bothersome
- Whether their other medications raise interaction risks
- How to taper or discontinue safely if stopping is needed

Sources

  1. https://www.drugpatentwatch.com/


Other Questions About Vilazodone :

2019 first generic drug approvals vilazodone hydrochloride tablets teva 9/30/2019 Vilazodone impurity manufacturers in usa? Fda vilazodone generic approved? Is vilazodone a controlled substance? Vilazodone price? Vilazodone viibryd manufacturing plant cost? Vilazodone name brand?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The evaluated claim about increased suicidal thoughts/behaviors in pediatric/young adult patients and close monitoring early in treatment and during dosage changes is directly supported by the label’s Boxed Warning, Section 5.1, and Pediatric Use (8.4).


Category Scores

Warnings
100
Excellent
Warnings
100
Excellent

Accurate Statements

Antidepressants (including VIIBRYD) increase the risk of suicidal thoughts and behaviors in pediatric and young adult patients, and patients should be closely monitored for clinical worsening and suicidality, especially early in treatment or when dosages change.
BoxWarning: increased risk in pediatric and young adult patients; closely monitor. Section 5.1: monitor all antidepressant-treated patients, especially initial few months and times of dosage changes; consider changing/discontinuing for emergent suicidality. 8.4: antidepressants increased risk in pediatric patients; cross-references BoxWarning/5.1.

Unsupported Statements


Contradictions


Important Omissions


Safety Assessment

Potential Patient Risk: Low
The claim accurately reflects labeled warnings and monitoring instructions regarding suicidality in pediatric and young adult patients.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score
49
Visibility
45
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

prescribed to treat major depressive disorder (MDD)


Core Claims
  • Vilazodone hydrochloride is described as the salt form of vilazodone
  • It is prescribed to treat major depressive disorder (MDD)
  • It works as a serotonin reuptake inhibitor and affects serotonin receptors
  • It increases serotonin signaling by inhibiting the serotonin transporter
  • It can raise the risk of serotonin syndrome when combined with other serotonergic drugs
Differentiators
  • Described as both a serotonin reuptake inhibitor and affecting serotonin receptors
  • Called a “serotonin modulator” antidepressant
  • Includes receptor activity such as 5-HT1A in addition to reuptake inhibition

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch 16%
50 #7 Yes